Coin-Leaf Desmodium (Desmodium styracifolium)
1. Identity and Botanical Description
1.1 Nomenclature and Taxonomy
Coin-leaf desmodium is the common English name for Desmodium styracifolium (Osbeck) Merr., a flowering leguminous herb whose botanical name honours the snowbell tree (Styrax), whose leaf shape the plant resembles. In the Encyclopedia of Life, Desmodium styracifolium is the species formally designated as Coin Leaf Desmodium, belonging to the family Leguminosae (Fabaceae).
The Desmodium genus belongs to the Fabaceae family and is widely distributed worldwide in tropical and subtropical zones, with many members having a long history of ancient, especially medicinal, uses. Within TCM taxonomy, the dried aerial parts of the plant are designated Herba Desmodii Styracifolii, also rendered in Chinese as 广金钱草 (Guǎng Jīn Qián Cǎo, meaning "Guangdong gold-coin herb"). The broader term Jin Qian Cao (金钱草, "Gold Coin Grass") is used in traditional Chinese herbal medicine and can refer to several herbal species identified by their native regions; the most common in the Chinese trade, listed in the Pharmacopoeia of the People's Republic of China, is Lysimachia christinae, but Desmodium styracifolium (as Guǎng Jīn Qiáncǎo) is specifically identified as a distinct pharmacopoeial entity.
Species including D. styracifolium (Osbeck) Merr. were incorporated in 2010 into the Pharmacopoeia of the People's Republic of China. Desmodium styracifolium is an important TCM listed in the Chinese Pharmacopoeia (2010 Edition) and has been applied to treat choloplania, some types of urinary disease like cholelithiasis, burning sense during urination, and edema.
1.2 Morphology and Natural Distribution
Desmodium styracifolium is a perennial herb growing to 0.8 m (approximately 2 ft 7 in), hermaphrodite (bearing both male and female organs), pollinated by insects, capable of fixing atmospheric nitrogen, and suited to sandy, loamy, or clay soils that are well drained. The species is mainly produced in the Chinese provinces of Guangdong and Guangxi. Its round, coin-shaped leaves — which give rise to its English common name — are distinctive among the genus. The plant belongs to the Leguminosae family and is also known in English as the snowbell-leaf tickclover herb.
1.3 Common Names and Synonymy
The plant is known by multiple vernacular and trade names across its range. In Chinese medicine it is most commonly encountered as Guǎng Jīn Qián Cǎo or Guǎngjīntiāncǎo. In traditional Vietnamese medicine the plant is known as Thóc lép or Đồng tiền. In English, "coin-leaf desmodium," "snowbell-leaf tickclover herb," and "Japanese clover" are all used. In traditional Vietnamese medicine, the medicinal herb has been used to treat diuretic symptoms, hyperthermia, renal stones, cardio-cerebrovascular diseases, and hepatitis. Across TCM literature, the herb name Herba Desmodii Styracifolii (Latin pharmacopoeial designation) corresponds directly to this species.
1.4 Pharmacopoeial and Regulatory Status
The pharmacopoeial drug substance consists of the dried overground part of the leguminous plant Desmodium styracifolium (Osb.) Merr., recorded in Part I of the Chinese Pharmacopoeia (2010 edition) for its efficacy in "disinhibiting dampness, abating jaundice, and disinhibiting urine and freeing strangury." A prescription preparation — a stranguria-treating and calculus-removing tablet containing D. styracifolium as its essential ingredient and also recorded in the Chinese Pharmacopoeia — is indicated for bladder dampness-heat, stone strangury with roughness and pain in the urethra, lithangiuria, and urinary infection attributed to dampness and heat in the liver, gallbladder, and urinary bladder.
2. Traditional and Historical Use
2.1 Traditional Chinese Medicine
The use of Desmodium species for ethnomedicinal purposes in China dates back to as early as 3,000 years ago. According to the theory of TCM, the herbs of the genus Desmodium have been used mainly to relieve internal heat or fever, neutralize toxins, inhibit pain, invigorate blood circulation, suppress cough, and alleviate dyspnea. Plants of the genus, including D. styracifolium, have a long history of medical use in Traditional Chinese Medicine to treat ailments including rheumatism, pyrexia, dysentery, wounds, cough, malaria, hepatitis, and hemoptysis.
The water decoction of Desmodium plants has been widely used in China to treat various diseases like asthma, typhoid fever, inflammations, malaria, infantile malnutrition, and dysentery. Specific to D. styracifolium, traditional Chinese medicine employed the herb to ease stranguria, disinhibit urine, and drain moisture in order to reduce jaundice, targeting diseases of the urinary tract (urolithiasis, haematuria, slow and painful urination, oedema, oliguria), hepatitis, jaundice, bile stasis, rheumatism, fever, dysentery, wound care, cough, malaria, haemoptysis, stomatitis, laryngitis, and urticaria.
The whole plant was used orally in the form of a decoction to treat urinary tract infections (24 g), urolithiasis (24–60 g), cholecystitis (30 g), stomatitis and laryngitis (15–30 g), and urticaria (60 g). For the treatment of infantile hypotrophy, it was used together with pork food. More than 20 species of the Desmodium genus have been applied over a 3,000-year history of traditional Eastern medicine, particularly in Chinese and Vietnamese cultures, where according to TCM theory they can "alleviate internal heat or fever, neutralize toxins, and promote blood circulation."
2.2 Traditional Vietnamese Medicine
D. styracifolium is a medicinal herb used in traditional Vietnamese medicine to treat urinary tract infections, fever, and kidney stones. In traditional Vietnamese medicine, the plant was used for the treatment of urinary tract diseases (urolithiasis, haematuria, slow and painful urination, and oliguria), as well as for biliary stasis, hepatitis, and inflammatory diseases.
2.3 Other Asian Traditions
Traditional medicinal uses have been described for species across 43 countries, with the genus Desmodium highlighting uses in inflammatory, gastrointestinal, and infectious processes, muscular pain, rheumatic, renal, and hepatic conditions. In Indonesia, related species of Desmodium were used for postpartum symptoms, lack of appetite, scabies, and itching. Preparations of leaves and roots were used for diarrhoea, dysentery, seizures, antispasmodic treatment, sympathomimetic effects, cough, asthma, and wound care.
2.4 Traditional Preparations
The principal traditional preparation of D. styracifolium is the aqueous decoction (shuǐ jiān jì in Chinese), in which the dried aerial parts are boiled in water and the resulting liquid consumed orally. In China, aqueous decoction of Desmodium plants has been widely used to treat a wide range of illnesses including rheumatism, fever, asthma, typhoid fever, dysentery, wound care, malaria, hepatitis, and hemoptysis. Topical applications in the form of a poultice from the whole plant were also recorded for conditions such as mastitis. The dried herb has also been used as a constituent in multi-herb formulas and, more recently, as a standardised tablet formulation in modern Chinese patent medicines.
3. Key Chemical Constituents and Active Compounds
3.1 Overview of Phytochemistry
The use of Desmodium plants in traditional medicine has encouraged phytochemical research. Scientists have isolated more than 200 compounds from representatives of this genus, including flavonoids, alkaloids, steroids, terpenoids, phenylpropanoids, and other components; however, only a portion of these compounds have been evaluated for biological activity. More than 50 chemical compounds have been reported specifically from D. styracifolium, including flavonoids, terpenoids, glycosides, phenols, and phytosterols.
Flavonoids and alkaloids are regarded as the major constituents and are perhaps responsible for most of the activities shown by plants of this genus. Phytochemical examination of Desmodium species has indicated the presence of isoflavones, glycosyl-flavonoids, coumarone-chromones, pterocarpans, triterpenoids, saponins, tetrahydroisoquinolines, phenylethylamines, indole-3-alkylamines, lipids, and other compound classes.
3.2 Flavonoids — The Primary Class
Flavonoids constitute the most pharmacologically investigated class of compounds in D. styracifolium. Research has identified a variety of C-glycosylated and O-glycosylated flavones and flavonoids. D. styracifolium contains flavonoid compounds such as vicenins and isovitexin, and a quantitative method for the detection of total flavonoids in this herb has been reported.
A key study using column chromatographic isolation identified the following compounds from the plant: 6-C-glycopyranosyl-8-C-arabinosyl apigenin, 6-C-glycopyranosyl luteolin, 6-C-glycopyranosyl-8-C-xylosyl apigenin, 6-C-glycopyranosyl-8-C-glucopyranosyl apigenin (schaftoside/isoschaftoside series), apigenin, luteolin, stigmasterol-3-O-β-D-glucopyranoside, β-daucosterol, and β-sitosterol.
Among all identified flavonoids, schaftoside (also rendered as "shaftoside" or "isovitexin-2′′-O-β-glucoside") has emerged as the marker compound most studied for biological activity and used for quality standardisation. D. styracifolium C-glycosylflavones vicenin-2, carlinoside, vicenin-1, schaftoside, and vicenin-3 have been identified as angiotensin-converting enzyme (ACE) inhibitors.
3.3 Alkaloids
Desmodilactone and styracifoline were identified as alkaloids from this plant and reported to have antidiabetic and antithrombotic activities. Chemical investigation of the aerial part of the Vietnamese plant resulted in the identification of a new compound, styracifoline, together with three known compounds: salicylic acid, quebrachitol, and a triterpenoid saponin glycoside.
Styracifoline exhibits anti-inflammatory and anti-diabetic effects by binding to the leptin receptor and its dephosphorylation, and by inhibiting PTP1B, which is responsible for insulin resistance through IRS-1 blocking.
3.4 Other Identified Compounds
The plant contains several bioactive compounds, including flavonoids, phenolic acids, polysaccharides, and volatile oils. Phytosterols including β-sitosterol and daucosterol have been isolated, as have triterpenoid saponins. The presence of salicylic acid and quebrachitol has also been confirmed in Vietnamese specimens.
4. Mechanisms of Action
4.1 Antiurolithic Mechanisms
Several experimental studies confirmed the potential of D. styracifolium to influence mineral metabolism, to decrease the concentration of constituents involved in the formation of urinary calculi, and to reduce mineral encrustation in the urinary tract, as well as to alleviate the damage caused by crystal structures. This beneficial impact is achieved through a combination of antioxidant and anti-inflammatory actions, along with urine alkalinisation.
In animal studies using a rat hydroxyproline-induced urolithiasis model, the total flavonoids of D. styracifolium (TFDS) demonstrated multiple complementary actions: TFDS significantly reduced crystalluria and calcium oxalate crystal deposits in kidney sections; decreased urinary oxalate excretion; alleviated pro-acidosis conditions; improved impaired renal function and renal epithelial cell injury; protected against oxidative stress changes by reducing malondialdehyde (MDA) content and increasing catalase (CAT) and glutathione peroxidase (GSH-Px) activities in renal homogenate; and attenuated expression of MCP-1, osteopontin (OPN), and TGF-β proteins. These results indicated that TFDS inhibits calcium oxalate formation through a combination of antioxidant, anti-inflammatory, and urine-alkalinising activities, along with lowering the concentration of urinary stone-forming constituents.
4.2 Choleretic and Hepatoprotective Mechanisms
The cholelitholytic, choleretic, and hepatoprotective effects of D. styracifolium plants have been confirmed, primarily ascribed to the activation of the hepatic LXRα receptor and the bile acid receptor, farnesoid X receptor (FXR), by the flavonoid schaftoside.
The action of schaftoside is associated with its ability to activate nuclear receptors in the liver and small intestine, such as the farnesoid X receptor (FXR) and liver Xα receptor (LXRα). Activation of FXR up-regulates bile salt concentration by promoting expression of the OSTα/β transporter and fibroblast growth factor 15/19 (FGF15/19) in the ileum, as well as increasing expression of bile salt export protein (BSEP)/ABCB11 and ABCB4 transporter in the liver. Activation of LXRα enhances cholesterol efflux from the gut and liver by stimulating ABCG5/8 and ABCA1 transporters, and additionally activates Cyp7A1/Cyp8B1, increasing the liver's production of bile salts.
4.3 Antioxidant and Anti-inflammatory Mechanisms
Phenolic compounds in the plant have the ability to scavenge reactive oxygen and nitrogen species, thereby preventing their activating influence on redox-sensitive transcription factors (NF-κB, STAT3, Nrf2, etc.). Flavonoids and isoflavonoids — including apigenin, genistein, kaempferol, luteolin, and quercetin — inhibit NF-κB both through IκBα and by activating SIRT1, Nrf2, and PPARγ signalling. The influence of polyphenols on pro-inflammatory and pro-oxidant cascades is further mitigated by their ability to suppress JAK-STAT3 signalling. Induction of Nrf2 and PPARγ enhances the expression of antioxidant, anti-inflammatory, and cytoprotective genes.
4.4 Antihypertensive Mechanisms
C-glycosylflavones from D. styracifolium — including vicenin-2, carlinoside, vicenin-1, schaftoside, and vicenin-3 — have been identified as angiotensin-converting enzyme (ACE) inhibitors, providing a plausible mechanism underlying the plant's reported hypotensive activity. The cardiovascular effects of D. styracifolium, which is officially listed in the Chinese Pharmacopoeia and used as a diuretic, have been demonstrated experimentally.
5. Scientific Evidence by Area of Use
5.1 Urolithiasis (Kidney and Urinary Tract Stones)
This is the most extensively studied application of D. styracifolium and the one with the broadest body of supporting preclinical evidence.
In vitro evidence: In vitro crystallisation studies have confirmed prophylactic effects against calcium oxalate (CaOx) stone formation. D. styracifolium extract confirmed the prophylaxis of CaOx stone formation in vitro, though little had previously been known about possible mechanisms in vivo.
Animal (in vivo) evidence: A systematic evaluation of the antilithic effects of D. styracifolium (Ds) was performed using a rat nephrolithiasis model with administered aqueous extracts. Adult male Wistar rats were fed with 5% ammonium oxalate forage to induce nephrolithiasis; after one week, rats were divided into eight groups and given low, medium, and high doses of Ds (275, 550, and 1,100 mg/kg) by gavage for three weeks. DS was confirmed to reduce CaOx deposition in the kidneys and alleviate crystal damage through anti-inflammatory and antioxidant functions. As a Chinese medicinal herb, D. styracifolium has been applied clinically to alleviate crystal-induced kidney injuries, but its effective components and specific mechanisms still need further exploration.
A further rat study using a hydroxyproline-induced model found that TFDS treatment produced favourable biochemical outcomes: these results indicated that TFDS had a beneficial effect on inhibition of CaOx formation in the rat kidney, probably through a combination of antioxidant, anti-inflammatory, urine alkalinising activities, and lowering the concentration of urinary stone-forming constituents, suggesting clinical implications in preventing oxidative renal cell injury and, ultimately, kidney stone formation.
Evidence strength: Urolithiasis is a widespread disease; although surgery and various drugs are used to treat it, high recurrence rates and drug side effects remain problematic. Flavonoids are presumed to have beneficial effects, yet very few have reached clinical use. The preclinical evidence base for D. styracifolium in nephrolithiasis is substantial and mechanistically coherent, but robust human randomised controlled trials (RCTs) are absent from the published literature. The evidence at the human level remains limited to traditional clinical use and observational data.
5.2 Cholelithiasis (Gallstones) and Biliary Effects
The cholelitholytic, choleretic, and hepatoprotective effects of D. styracifolium have been confirmed in experimental studies, primarily ascribed to the activation of the hepatic LXRα receptor and the bile acid receptor (FXR) by the flavonoid schaftoside. A study on schaftoside specifically demonstrated prevention of cholesterol gallstone disease in a lithogenic diet-induced C57BL/6 mouse model. New strategies for the prevention and treatment of urolithiasis and cholelithiasis may rely on the promising development of dosage forms of D. styracifolium with subsequent preclinical and clinical trials.
Evidence strength: Preclinical (cell-based and animal) evidence is available for cholelitholytic and choleretic effects. Human clinical trial data are absent from the published scientific literature. Traditional use is extensive for this indication.
5.3 Hepatoprotective Activity
Experimental studies have demonstrated that extracts of Desmodium plants have a wide range of pharmacological properties, including hepatoprotective effects, as well as improvements in cardiovascular and cerebrovascular functions and immune system regulation. The hepatoprotective mechanism is linked to the same FXR/LXRα signalling pathway activated by schaftoside, as well as the general antioxidant properties of the plant's polyphenol fraction. Studies have also demonstrated that schaftoside activates the farnesoid X receptor, thereby ameliorating acetaminophen-induced hepatotoxicity by modulating oxidative stress and inflammation.
The main chemical components of D. styracifolium are flavonoids and volatile components, which are used widely for treatments including promoting urination, promoting gallbladder function, anti-stone activity, anti-inflammatory action, antioxidant effects, and protecting the cardiovascular system.
Evidence strength: Preclinical (animal and cell) evidence supports hepatoprotective activity. No human clinical trials are available.
5.4 Anti-inflammatory Activity
A study aimed to determine the anti-colitic effect of D. styracifolium extract in ulcerative colitis (UC) mice and its possible antioxidative mechanisms. Phenolic antioxidants and free radical scavenging activities of the herb extract were determined, and LCMS was used to identify phenolic compounds. Ulcerative colitis in C57BL/6 SPF mice was induced with dextran sodium sulfate (DSS); mice were treated with two doses of the DS extract during a 7-day experiment. Colon length, spleen weight, histopathological changes in colonic tissues, and the disease activity index (DAI) were measured. The bioactive antioxidants in DS extract were identified as flavonoids; DS-treated UC mice had a lower DAI than untreated UC mice, and herbal treatment downregulated the expressions of pro-inflammatory cytokine genes in colonic tissues.
Evidence strength: This evidence is from an animal model only. Among 45 biological activities experimentally evaluated for the genus, antioxidant, antimicrobial, anti-inflammatory, hepatoprotective, and antinociceptive properties were the most reported. No human RCTs exist for the anti-inflammatory indication.
5.5 Antidiabetic and Metabolic Effects
The medicinal herb D. styracifolium has been used in traditional Vietnamese medicine to treat cardio-cerebrovascular diseases, among other conditions. A molecular docking simulation on styracifoline revealed its potential inhibitory activity toward tyrosine phosphatase 1B (PTP1B: docking score −14.6 kcal/mol), α-glucosidase (docking score −15.2 kcal/mol), oligo-1,6-glucosidase (docking score −15.4 kcal/mol), and the purinergic receptor P2Y1R (docking score −14.6 kcal/mol).
These findings were intended to encourage further in vitro and in vivo tests to verify the antidiabetic and antiplatelet activities of styracifoline. Styracifoline exhibits anti-inflammatory and anti-diabetic effects by binding to the leptin receptor and its dephosphorylation, and inhibiting PTP1B, which is responsible for insulin resistance through IRS-1 blocking; this alkaloid also activates STAT3.
The genus Desmodium, traditionally used in Chinese medicine, has been associated with antidiabetic activity, antioxidant activity, and anti-inflammatory properties, which may be attributed to the flavonoids and alkaloids.
Evidence strength: Evidence is limited to in silico (molecular docking) and in vitro assays for antidiabetic effects. Animal studies and human trials are required to validate these findings.
5.6 Antihypertensive and Cardiovascular Effects
Among the reported uses of D. styracifolium are protecting the cardiovascular system and promoting urination, which may contribute to blood pressure reduction. The ACE-inhibitory activity of the plant's C-glycosylflavones provides a plausible molecular mechanism. An early published study by Ho, Wong, and Chiu (1989) documented "the hypotensive action of Desmodium styracifolium and Clematis chinensis" in the American Journal of Chinese Medicine, representing one of the earliest experimental investigations of this property.
Evidence strength: The antihypertensive evidence derives from older pharmacological experiments and ACE-inhibition assays. Controlled human data are unavailable.
5.7 Antimicrobial Activity
Phytochemical investigation of D. styracifolium resulted in the determination of antimicrobial compounds including flavonoid C-glycosides and isoflavonoids. Additional in vitro antimicrobial studies have confirmed activity against both phytopathogenic fungi and bacteria. Orientin and vitexin, common flavonoid 8-C-glycosides present in Desmodium species, were found to directly inhibit Staphylococcus aureus, Escherichia coli, and Bacillus subtilis in laboratory assays.
Evidence strength: In vitro antimicrobial evidence only. No clinical antimicrobial trials are available.
5.8 Pharmacokinetic Modelling — Schaftoside
A physiologically based pharmacokinetic (PBPK) modelling study of schaftoside — the primary marker flavonoid — established a model providing useful insight for dose selection of the total flavonoids of D. styracifolium in different populations, and offered a feasible approach for the assessment of efficacy and safety of herbal medicines. This represents a step toward rationalising clinical dosing but does not substitute for clinical outcome data.
6. Body Systems and Health Areas Associated
- Renal and urinary system: D. styracifolium is used in traditional oriental medicine mainly for the treatment of urinary tract diseases (urolithiasis, haematuria, slow and painful urination, and oliguria).
- Hepatobiliary system: Cholelithiasis, cholestasis, hepatitis, and jaundice are historically associated indications supported by mechanistic preclinical data.
- Gastrointestinal system: Traditional uses include dysentery, diarrhoea, and more recently, colitis has been studied in an animal model.
- Cardiovascular system: Historically used as a diuretic and for blood pressure management; ACE-inhibitory C-glycosylflavones identified.
- Metabolic / endocrine system: Preclinical and in silico evidence for antidiabetic and anti-obesity properties, linked to PTP1B and α-glucosidase inhibition by styracifoline.
- Immune and inflammatory system: Anti-inflammatory effects documented via NF-κB, STAT3, and Nrf2/PPARγ modulation in preclinical models.
- Respiratory system: Traditional use for cough, asthma, and dyspnea is recorded across multiple TCM sources, though no modern clinical research supports this indication.
7. Dosage Forms and Reported Dosages
7.1 Traditional Decoction
The whole plant was used orally in the form of a decoction to treat urinary tract infections (24 g dried herb), urolithiasis (24–60 g), cholecystitis (30 g), stomatitis and laryngitis (15–30 g), and urticaria (60 g). These dosages reflect traditional Chinese medical practice as recorded in the literature, expressed as the mass of dried aerial plant material boiled in water.
7.2 Modern Pharmaceutical Preparations
The pharmacopoeial drug substance is the dried overground part of the plant, recorded in the Chinese Pharmacopoeia (2010 edition) with efficacy in disinhibiting dampness, abating jaundice, and freeing strangury. A prescription preparation — a stranguria-treating and calculus-removing tablet — contains D. styracifolium as its essential ingredient; this tablet has been associated with an overdose schedule of 6 times a day, three pills at a time, as sugar-coated or film-coated tablets, each pill containing 0.12 g dry extract.
Newer pharmaceutical development has focused on standardised total-flavonoid capsule formulations. The traditional preparation still carries issues such as an original pharmaceutical process, difficulties in quality control, inaccurate quantitative detection methods, and overdosing; therefore, there is a need to research and develop new formulations of total flavonoids of D. styracifolium with safety and efficacy, controllable quality, and high dissolution rates.
7.3 Dosages Used in Preclinical Studies
In the rat nephrolithiasis study, adult male Wistar rats were administered aqueous extracts of D. styracifolium at low, medium, and high doses of 275, 550, and 1,100 mg/kg body weight per day by gavage for three weeks. These are animal experimental doses and cannot be directly extrapolated to human dosing.
8. Safety Considerations and Known Interactions
8.1 General Safety Profile
Chinese herbs Desmodium styracifolium and Pyrrosiae petiolosa have been widely used to treat urolithiasis with few reported side effects in traditional Chinese medicine. Formal systematic toxicological studies specifically for D. styracifolium are limited in the peer-reviewed literature. The 2,000-year history of use as a food and medicine ingredient in China provides a long record of empirical safety, but this does not substitute for rigorous modern toxicological evaluation.
8.2 Quality Control and Adulteration Concerns
The term Jin Qian Cao (Gold Coin Grass) in Chinese medicine refers to several herbal species identified by their native regions, with Lysimachia christinae being the most common in the Chinese trade and listed in the Pharmacopoeia of the People's Republic of China. This creates a documented risk of confusion and substitution between D. styracifolium (Guǎng Jīn Qiáncǎo) and L. christinae (Jīn Qiáncǎo), which are distinct botanical and chemical entities. Practitioners and consumers should verify that the specific pharmacopoeial name Herba Desmodii Styracifolii or the scientific name Desmodium styracifolium is used when this species is intended.
8.3 Interactions with Drug Metabolising Systems
The action of schaftoside — the marker flavonoid — is associated with its ability to activate nuclear receptors including the farnesoid X receptor (FXR) and liver Xα receptor (LXRα). Activation of FXR up-regulates bile salt concentration by promoting expression of specific transporters (OSTα/β, FGF15/19) in the ileum and increasing expression of bile salt export protein (BSEP)/ABCB11 and ABCB4 transporters in the liver. Modulation of these hepatic transporters raises the theoretical possibility of pharmacokinetic interactions with co-administered drugs that are substrates of bile salt export pathways, though no direct interaction studies in humans have been published.
8.4 ACE Inhibitory Properties — Potential Blood Pressure Interaction
Given that several C-glycosylflavones from the plant have demonstrated ACE-inhibitory activity, concurrent use with antihypertensive medications — particularly ACE inhibitors or angiotensin receptor blockers — warrants attention, though the clinical significance of this interaction has not been characterised in human studies.
8.5 Evidence Gaps
The lack of clinical trials studying medicines derived from this plant and performed in conformity with the requirements of evidence-based medicine remains the most significant limitation in evaluating its safety and efficacy. New strategies for prevention and treatment of urolithiasis, cholelithiasis, type 2 diabetes mellitus, metabolic syndrome, and inflammatory processes may rely on the promising development of dosage forms of D. styracifolium with their subsequent preclinical and clinical trials. Systematic reproductive toxicity, genotoxicity, and long-term carcinogenicity data from modern study designs have not been published in the accessible literature.
9. Summary of Evidence Strength by Indication
- Urolithiasis (calcium oxalate): Substantial preclinical evidence (in vitro + multiple animal models); no published human RCTs. Strongest evidence base for this genus.
- Cholelithiasis / biliary disorders: Mechanistically coherent preclinical evidence; no human clinical trials.
- Hepatoprotection: Preclinical evidence; no human data.
- Anti-inflammatory / colitis: Animal model evidence; no human data.
- Antidiabetic: In silico (molecular docking) and in vitro only; no animal or human trials for this specific species.
- Antihypertensive: Early pharmacological experiments and ACE-inhibition assays; no human RCTs.
- Antimicrobial: In vitro evidence only.
References
Go back